Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Conditions
Keywords
transthyretin cardiac amyloidosis, transthyretin amyloid cardiomyopathy
Brief summary
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.
Interventions
DIAGNOSTIC_TEST99mTc-pyrophosphate Single Photon Emission Computed Tomography
All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
Sponsors
Montefiore Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023
Exclusion criteria
* Did not have a transthoracic echocardiogram in our medical records
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ATTR-CM Diagnosis | During the index PYP scan within the study time frame parameters of the retrospective review (between 2014 and 2023) | The number of patients who underwent a PYP SPECT scan diagnostic of ATTR-CM will be assessed and reported |
| Mortality | Within the study time frame parameters of the retrospective review (between 2014 and 2023) | The number of patients who died from all-cause mortality will be tabulated and reported |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart failure hospitalizations | Within the study time frame parameters of the retrospective review (between 2014 and 2023) | The number of patients admitted to the hospital with a primary diagnosis of heart failure will be tabulated and reported |
| Total Hospitalizations | Within the study time frame parameters of the retrospective review (between 2014 and 2023) | The number of patients admitted to the hospital with any diagnosis will be tabulated and reported |
Countries
United States
Outcome results
None listed